Immune Checkpoint Inhibitors (ICI) in the Functional Cure of Hepatitis B: A Narrative Review
), I Ketut Mariadi(2), Gde Somayana(3),
(1) Bali Mandara General Hospital, Bali, Indonesia
(2) Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Udayana University/ Prof. Dr. I.G.N.G. Ngoerah General Hospital, Bali, Indonesia
(3) Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Udayana University/ Prof. Dr. I.G.N.G. Ngoerah General Hospital, Bali, Indonesia
Corresponding Author
Abstract
Chronic hepatitis B (CHB) remains a major global health burden, largely due to the persistence of covalently closed circular DNA (cccDNA) within infected hepatocytes, which hinders complete viral eradication despite long-term antiviral therapy. In recent years, immune checkpoint inhibitors (ICIs) have emerged as a potential therapeutic strategy by restoring exhausted antiviral immune responses. This review explores the mechanisms of action of ICIs, their current application in hepatitis B virus (HBV) infection, and their potential role in achieving a functional cure. Available evidence indicates that ICIs targeting programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) are capable of partially restoring HBV-specific T-cell function and reducing intrahepatic cccDNA transcriptional activity. Early-phase clinical studies have demonstrated encouraging outcomes, including declines in hepatitis B surface antigen (HBsAg) levels and occasional HBsAg loss; however, consistent achievement of a functional cure remains limited. Notably, combination strategies involving ICIs with therapeutic vaccines or nucleos(t) ide analogues appear to enhance antiviral efficacy compared with monotherapy. In conclusion, ICIs represent a promising adjunctive approach for CHB treatment and may contribute to the pursuit of a functional cure. Nevertheless, further well-designed clinical trials are required to establish their long-term safety, optimal treatment combinations, and effectiveness, particularly in HBV-endemic populations.
Keywords
References
Tripathi N, Mousa OY. Hepatitis B. In: Gut Instincts: A Clinician’s Handbook of Digestive and Liver Diseases. 2023:227–35.
Nelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clin Liver Dis. 2016;20:607–28.
Sheena BS, Hiebert L, Han H, Ippolito H, Abbasi-Kangevari M, Abbasi-Kangevari Z, et al. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7(9):796–829.
Su TH, Liu CJ. Combination therapy for chronic hepatitis B: current updates and perspectives. Gut Liver. 2017;11(5):590–603.
Saeed U, Piracha ZZ, Khan M, Tariq MN, Gilani SS, Raza M, et al. Cracking the code of HBV persistence: cutting-edge approaches to targeting cccDNA in chronic hepatitis B with or without pyogenic liver abscesses. Front Med (Lausanne). 2025;12:1–15.
Boonstra A, Sarı G. HBV cccDNA: the molecular reservoir of hepatitis B persistence and challenges to achieve viral eradication. Biomolecules. 2025;15(1):62.
Maepa MB, Ely A, Kramvis A, Bloom K, Naidoo K, Simani OE, et al. Hepatitis B virus research in South Africa. Viruses. 2022;14(9):1939.
Freeland C, Farrell S, Kumar P, Kamischke M, Jackson M, Bodor S, et al. Common concerns, barriers to care, and the lived experience of individuals with hepatitis B: a qualitative study. 2021.
Mohareb AM, Kouamé MG, Nouaman M, Kim AY, Larmarange J, Neilan AM, et al. What does the scale-up of long-acting HIV pre-exposure prophylaxis mean for the global hepatitis B epidemic? J Int AIDS Soc. 2024;27(3).
Phillips SM, Jagatia R, Chokshi S. Novel therapeutic strategies for chronic hepatitis B. Virulence. 2022;13(1):1111–32.
Atanaw T, Girmay G, Zemene A, Assefa M, Eshetie T, Bewket G, et al. Seroprevalence of hepatitis B and C viruses and some possible associated factors among cancer patients at the oncology treatment center, Gondar, Northwest Ethiopia: a cross-sectional study. PLoS One. 2024;19(8):e0308161.
Mon HC, Lee PC, Hung YP, Hung YW, Wu CJ, Lee CJ, et al. Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy. J Hepatol. 2025;82(1):51–61.
Wieland D, Hofmann M, Thimme R. Overcoming CD8+ T-cell exhaustion in viral hepatitis: lessons from the mouse model and clinical perspectives. Dig Dis. 2017;35(4):334–8.
Li S, Li N, Yang S, Deng H, Li Y, Wang Y, et al. The study of immune checkpoint inhibitors in chronic hepatitis B virus infection. Int Immunopharmacol. 2022;109:108842.
Lok ASF. Toward a functional cure for hepatitis B. Gut Liver. 2024;18(4):593–601.
Younis A, Gribben J. Immune checkpoint inhibitors: fundamental mechanisms, current status and future directions. Immuno. 2024;4(3):186–210.
Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8).
Mon HC, Lee PC, Chi CT, Huang YH. Effect of immune checkpoint inhibitors on patients with hepatitis B virus infection. J Chin Med Assoc. 2025;88(2):93–7.
Ligat G, Goto K, Verrier E, Baumert TF. Targeting viral cccDNA for cure of chronic hepatitis B. Curr Hepatol Rep. 2020;19(3):235–44.
Gane E, Verdon DJ, Brooks AE, Gaggar A, Nguyen AH, Subramanian GM, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study. J Hepatol. 2019;71(5):900–7.
Su M, Ye T, Wu W, Shu Z, Xia Q. Possibility of PD-1/PD-L1 inhibitors for the treatment of patients with chronic hepatitis B infection. Dig Dis. 2024;42(1):53–60.
Kothapalli A, Khattak MA. Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series. Melanoma Res. 2018;28(2):155–8.
El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–502.
Qian J, Xie Y, Mao Q, Xie Q, Gu Y, Chen X, et al. A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally suppressed patients with chronic hepatitis B who are HBeAg-negative. Hepatology. 2025;81(4):1328–42.
Gehring AJ, Mendez P, Richter K, Ertl H, Donaldson EF, Mishra P, et al. Immunological biomarker discovery in cure regimens for chronic hepatitis B virus infection. J Hepatol. 2022;77(2):525–38.
Sorensen H, Evans T, Tait D. A phase 2b, open-label study to evaluate the efficacy, safety, tolerability, immunogenicity and treatment regimens of VTP-300 combined with low-dose nivolumab in chronic hepatitis B infection. Hepatology. 2023;77(Suppl 1).
Inoue T, Matsui T, Tanaka Y. Novel strategies for the early diagnosis of hepatitis B virus reactivation. Hepatol Res. 2021;51(10):1033–43.
Godbert B, Petitpain N, Lopez A, Nisse YE, Gillet P. Hepatitis B reactivation and immune check point inhibitors. Dig Liver Dis. 2021;53(4):452–5.
Lombardi A, Mondelli MU. Immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects. Aliment Pharmacol Ther. 2019;50(8):872–84.
Li M, Sack J, Bell P, Rahma OE, Srivastava A, Grover S, et al. Utility of liver biopsy in diagnosis and management of high-grade immune checkpoint inhibitor hepatitis in patients with cancer. JAMA Oncol. 2021;7(11):1711.
Citarella F, Galletti A, Russano M, Gallo P, Vespasiani-Gentilucci U, Picardi A, et al. Steroid-refractory immune related hepatitis may hide viral reactivation. Future Sci OA. 2020;6(9).
Cao W, Wei J, Wang N, Xu H, Xiao M, Huang L, et al. Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy. Blood. 2020;136(4):516–9.
Ifuku H, Kusumoto S, Tanaka Y, Totani H, Ishida T, Okada M, et al. Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia–lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab. Hepatol Res. 2015;45(13):1363–7.
Broquetas T, Carrión JA. Past, present, and future of long-term treatment for hepatitis B virus. World J Gastroenterol. 2023;29(25):3964–83.
Article Metrics
Abstract View
: 138 times
Download : 90 times
DOI: 10.24871/271202660-69
Refbacks
- There are currently no refbacks.
